Actively Recruiting
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
Led by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Updated on 2025-09-18
608
Participants Needed
24
Research Sites
254 weeks
Total Duration
On this page
Sponsors
F
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Lead Sponsor
E
European Commission
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving anthracyclines.
CONDITIONS
Official Title
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older diagnosed with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer
- Scheduled to undergo chemotherapy including a cumulative anthracycline dose of at least 240 mg/m2
- Left ventricular ejection fraction (LVEF) greater than 40% on screening echocardiography
- Presence of at least one risk factor for cardiotoxicity, such as previous coronary artery disease, age 65 years or older, hypertension, chronic kidney disease, current or former smoking, obesity (BMI ≥ 30 kg/m2), left ventricular hypertrophy, high alcohol intake, sinus rhythm on ECG, diabetes (except those treated with sulfonylureas or with neuropathy), or previous non-anthracycline chemotherapy
- Signed informed consent form
You will not qualify if you...
- Previous treatment with anthracyclines for any cancer before the current episode
- Clinical diagnosis of heart failure
- Permanent atrial fibrillation
- Severe valvular or sub-valvular heart disease
- Severe peripheral arterial disease in the upper limbs or arteriovenous shunt in the arm selected for RIPC
- Clinical diagnosis of diabetic neuropathy
- Contraindications for cardiac magnetic resonance imaging, including severe claustrophobia or implanted biomedical cardiac devices such as pacemakers, ICDs, or CRT
- Severe thrombocytopenia (platelets below 50,000/µL) within the last 3 months
- Participation in other clinical trials
- Inability to provide consent or comply with study follow-up procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
Aarhus University
Aarhus, Denmark
Actively Recruiting
2
Hospital Jaques Monod, El Havre
Montivilliers, France
Not Yet Recruiting
3
Henri Becquerel
Rouen, France
Actively Recruiting
4
University Hospital Duesseldorf UDUS
Düsseldorf, Germany
Actively Recruiting
5
Amsterdam UMC
Amsterdam, Netherlands
Not Yet Recruiting
6
Hospital da Luz Learning Health (GLSMED)
Lisbon, Portugal
Actively Recruiting
7
IPO Lisboa
Lisbon, Portugal
Actively Recruiting
8
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, Spain
Not Yet Recruiting
9
Centro Medico Teknon
Barcelona, Spain
Actively Recruiting
10
Instituto Catalán de Oncología
Barcelona, Spain
Actively Recruiting
11
Hospital Universitario Virgen de las Nieves
Granada, Spain
Actively Recruiting
12
Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Madrid, Spain
Actively Recruiting
13
Fundacion Jimenez Diaz
Madrid, Spain
Actively Recruiting
14
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Actively Recruiting
15
Hospital Infanta Leonor
Madrid, Spain
Actively Recruiting
16
Hospital Puerta de Hierro
Madrid, Spain
Actively Recruiting
17
Hospital Universitario 12 de Octubre
Madrid, Spain
Actively Recruiting
18
Hospital Universitario Clínico San Carlos
Madrid, Spain
Actively Recruiting
19
Hospital Universitario la Paz
Madrid, Spain
Actively Recruiting
20
Hospital Universitario Ramon y Cajal
Madrid, Spain
Actively Recruiting
21
Hospital Universitario Ruber Juan Bravo
Madrid, Spain
Actively Recruiting
22
Hospital Universitario de Salamanca
Salamanca, Spain
Actively Recruiting
23
Hospital Universitario Virgen del Rocío
Seville, Spain
Actively Recruiting
24
Hospital Clinico Universitario de Valladolid
Valladolid, Spain
Actively Recruiting
Research Team
B
Borja Ibañez, MD PhD FESC
CONTACT
N
Noemi Escalera
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here